Inhibition of PRKAA/AMPK (Ser485/491) phosphorylation by crizotinib induces cardiotoxicity via perturbing autophagosome-lysosome fusion

• Published in: Autophagy 2024-02, Vol.20 (2), p.416-436
• Main Authors: Xu, Zhifei, Pan, Zezheng, Jin, Ying, Gao, Zizheng, Jiang, Feng, Fu, Huangxi, Chen, Xueqin, Zhang, Xiaochen, Yan, Hao, Yang, Xiaochun, Yang, Bo, He, Qiaojun, Luo, Peihua
• Format: Article
• Language: English
• Subjects: Adenosine Monophosphate; AMP-Activated Protein Kinases - metabolism; Animals; Autophagosome-lysosome fusion; Autophagosomes - metabolism; autophagy; Autophagy - genetics; Carcinoma, Non-Small-Cell Lung - metabolism; Cardiotoxicity; crizotinib; Crizotinib - metabolism; Lung Neoplasms - metabolism; Lysosomes - metabolism; Macroautophagy; Metformin; Mice; Myosins - metabolism; Peptides - metabolism; Phosphatidylinositol 3-Kinases - metabolism; Phosphorylation; PRKAA/AMPK; Protein-Tyrosine Kinases - metabolism; Proto-Oncogene Proteins - metabolism; Receptor Protein-Tyrosine Kinases - metabolism; Tyrosine Kinase Inhibitors
• ISSN: 1554-8627; 1554-8635; 1554-8635
• DOI: 10.1080/15548627.2023.2259216

Crizotinib, a small-molecule tyrosine kinase inhibitor targeting ALK, MET and ROS1, is the first-line drug for ALK-positive metastatic non-small cell lung cancer and is associated with severe, sometimes fatal, cases of cardiac failure, which increases the risk of mortality. However, the underlying mechanism remains unclear, which causes the lack of therapeutic strategy. We established in vitro and in vivo models for crizotinib-induced cardiotoxicity and found that crizotinib caused left ventricular dysfunction, myocardial injury and pathological remodeling in mice and induced cardiomyocyte apoptosis and mitochondrial injury. In addition, we found that crizotinib prevented the degradation of MET protein by interrupting autophagosome-lysosome fusion and silence of MET or re-activating macroautophagy/autophagy flux rescued the cardiomyocytes death and mitochondrial injury caused by crizotinib, suggesting that impaired autophagy activity is the key reason for crizotinib-induced cardiotoxicity. We further confirmed that recovering the phosphorylation of PRKAA/AMPK (Ser485/491) by metformin re-activated autophagy flux in cardiomyocytes and metformin rescued crizotinib-induced cardiomyocyte injury and cardiac complications. In summary, we revealed a novel mechanism for crizotinib-induced cardiotoxicity, wherein the crizotinib-impaired autophagy process causes cardiomyocyte death and cardiac injury by inhibiting the degradation of MET protein, demonstrated a new function of impeded autophagosome-lysosome fusion in drugs-induced cardiotoxicity, pointed out the essential role of the phosphorylation of PRKAA (Ser485/491) in autophagosome-lysosome fusion and confirmed metformin as a potential therapeutic strategy for crizotinib-induced cardiotoxicity. Abbreviations and Acronyms: AAV: adeno-associated virus; ACAC/ACC: acetyl-Co A carboxylase; AMP: adenosine monophosphate; AMPK: AMP-activated protein kinase; ATG5: autophagy related 5; ATG7: autophagy related 7; CHX: cycloheximide; CKMB: creatine kinase myocardial band; CQ: chloroquine; c-PARP: cleaved poly (ADP-ribose) polymerase; DAPI: 4ʹ6-diamidino-2-phenylindole; EF: ejection fraction; FOXO: forkhead box O; FS: fractional shortening; GSEA: gene set enrichment analysis; H&E: hematoxylin and eosin; HF: heart failure; HW: TL: ratio of heart weight to tibia length; IR: ischemia-reperfusion; KEGG: Kyoto encyclopedia of genes and genomes; LAMP2: lysosomal-associated membrane protein 2; LDH: lactate dehydrogenase; MCMs: mou